Aptevo Therapeutics Inc. announced a new solid tumor strategy on July 27, 2026, centered on a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone. This platform-derived innovation is designed to support multiple therapeutic approaches, including radiopharmaceuticals, T-cell engagers, and other immune-based therapies. The company intends to use this reusable targeting architecture to expand its oncology pipeline, enhance tumor localization, and increase opportunities for strategic partnerships with large pharmaceutical companies. Aptevo is a clinical-stage biotechnology company developing multispecific immuno-oncology therapeutics.

Aptevo Therapeutics Inc. entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund on June 29, 2026, to receive $1,499,951.00 in reimbursement-based funding. The funds are intended to support Investigational New Drug (IND)-enabling studies for APVO451, a trispecific antibody candidate for solid tumor indications, through an expected project period ending in June 2028. Aptevo Therapeutics Inc. is a biotechnology company focused on developing therapeutic antibody candidates for cancer treatment.